What is TCRX's current stock price?

TCRX (TScan Therapeutics, Inc.) is currently trading at $1.06 with a market cap of $64.7M.

What sector is TScan Therapeutics, Inc. in?

TScan Therapeutics, Inc. (TCRX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TCRX a good stock to buy?

Analysts have a Buy consensus on TCRX with a price target of $7.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TCRX TScan Therapeutics, Inc.

Healthcare

$1.06+3.92%ClosedMarket Cap: $64.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.42

P/S

7.09

EV/EBITDA

0.03

DCF Value

$-3.83

FCF Yield

-193.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

92.4%

Operating Margin

-1408.7%

Net Margin

-1360.6%

ROE

-91.9%

ROA

-61.5%

ROIC

-67.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$982.0K	$-28.7M	$—
Q4 null	$2.6M	$-23.0M	$—
FY null	$10.3M	$-129.8M	$—
Q3 null	$2.5M	$-35.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.50

Target (Median)

$7.50

Target Range

$3.00 - $12.00

1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

WedbushOutperform

2026-03-05

HC Wainwright & Co.Buy

2025-11-13

NeedhamBuy

2025-11-04

BTIGNeutral

2025-11-04

Trading Activity

Insider Trades

View All

Woods Keithdirector

SellFri May 22

Nicholson Garry Adirector

SellFri May 22

Klencke Barbaradirector

SellFri May 22

Gruia Gabrieladirector

SellFri May 22

Dorton Katinadirector

SellFri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.06

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Peers